Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects-Reference-Cited by-同舟云学术

Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects

Published:2017-08-18 Issue:4 Volume:10 Page:73
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Guevara Natalia,Maldonado Cecilia,Uría Manuel,González Raquel,Ibarra Manuel,Alvariza Silvana,Carozzi Antonella,Azambuja Carlos,Fagiolino Pietro,Vázquez Marta

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

http://www.mdpi.com/1424-8247/10/3/73/pdf

Reference32 articles.

1. PharmGKB summary

2. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients

3. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

4. Phenytoin;Eadie,2009

5. METABOLISM OF ANTICONVULSANT DRUGS

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs;JAMA Network Open;2024-08-08

2. Pharmacogenetics in Epilepsy and Refractory Epilepsy;Pharmacoresistance in Epilepsy;2023

3. The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug‐resistant epilepsy;Epilepsia Open;2021-10

4. Genetic and clinical risk factors associated with phenytoin‐induced cutaneous adverse drug reactions in Thai population;Pharmacoepidemiology and Drug Safety;2020-03-05

5. Estudio del índice nivel/dosis de la fenitoína en pacientes epilépticos voluntarios de Mérida;Revista Médica Clínica Las Condes;2020-03